Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.

Fibroblast growth factor-23 (FGF-23) is one of the circulating phosphaturic factors associated with renal phosphate wasting. Fgf-23-/- animals show extremely high serum levels of phosphate and 1,25-dihydroxyvitamin D3, along with abnormal bone mineralization and soft tissue calcifications. To determine the role of vitamin D in mediating altered phosphate homeostasis and skeletogenesis in the Fgf-23-/- mice, we generated mice lacking both the Fgf-23 and 1alpha-hydroxylase genes (Fgf-23-/-/1alpha(OH)ase-/-). In the current study, we have identified the cellular source of Fgf-23 in adult mice. In addition, loss of vitamin D activities from Fgf-23-/- mice reverses the severe hyperphosphatemia to hypophosphatemia, attributable to increased urinary phosphate wasting in Fgf-23-/-/1alpha(OH)ase-/- mice, possibly as a consequence of decreased expression of NaPi2a. Ablation of vitamin D from Fgf-23-/- mice resulted in further reduction of total bone mineral content and bone mineral density and reversed ectopic calcification of skeleton and soft tissues, suggesting that abnormal mineral ion homeostasis and impaired skeletogenesis in Fgf-23-/- mice are mediated through enhanced vitamin D activities. In conclusion, using genetic manipulation studies, we have provided evidence for an in vivo inverse correlation between Fgf-23 and vitamin D activities and for the severe skeletal and soft tissue abnormalities of Fgf-23-/- mice being mediated through vitamin D.

[1]  M. Razzaque,et al.  Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. , 2006, Trends in molecular medicine.

[2]  M. Razzaque,et al.  Premature aging‐like phenotype in fibroblast growth factor 23 null mice is a vitamin D‐mediated process , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  T. Shimada,et al.  Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. , 2005, American journal of physiology. Renal physiology.

[4]  M. Razzaque,et al.  FGF-23, vitamin D and calcification: the unholy triad. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  S. Kato,et al.  Role of the vitamin D receptor in FGF23 action on phosphate metabolism. , 2005, The Biochemical journal.

[6]  K. White,et al.  Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. , 2005, Bone.

[7]  R. Bergman,et al.  Absence of Intraepidermal Glycosyltransferase ppGalNac-T3 Expression in Familial Tumoral Calcinosis , 2005, The American Journal of dermatopathology.

[8]  M. Econs,et al.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  S. Mooney,et al.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[10]  D. Behar,et al.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders , 2005, Journal of Molecular Medicine.

[11]  P. Orlik,et al.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.

[12]  S. Kato,et al.  Circulating FGF-23 Is Regulated by 1α,25-Dihydroxyvitamin D3 and Phosphorus in Vivo* , 2005, Journal of Biological Chemistry.

[13]  M. Razzaque,et al.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[14]  S. Peleg,et al.  Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. , 2004, Endocrinology.

[15]  D. Miao,et al.  Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. , 2004, Endocrinology.

[16]  S. Ladhani,et al.  Presentation of vitamin D deficiency , 2004, Archives of Disease in Childhood.

[17]  C. Ohlsson,et al.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. , 2004, Endocrinology.

[18]  F. Glorieux,et al.  Rescue of the phenotype of CYP27B1 (1α-hydroxylase)-deficient mice , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  D. Miao,et al.  Inactivation of the 25-Hydroxyvitamin D 1α-Hydroxylase and Vitamin D Receptor Demonstrates Independent and Interdependent Effects of Calcium and Vitamin D on Skeletal and Mineral Homeostasis* , 2004, Journal of Biological Chemistry.

[20]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[21]  T. Yoneya,et al.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. , 2004, Biochemical and biophysical research communications.

[22]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[23]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[24]  S. Fukumoto,et al.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. , 2003, The New England journal of medicine.

[25]  F. Glorieux,et al.  Rescue of the Pseudo‐Vitamin D Deficiency Rickets Phenotype of CYP27B1‐Deficient Mice by Treatment With 1,25‐Dihydroxyvitamin D3: Biochemical, Histomorphometric, and Biomechanical Analyses , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  M. Razzaque,et al.  Role of collagen-binding heat shock protein 47 and transforming growth factor-beta1 in conjunctival scarring in ocular cicatricial pemphigoid. , 2003, Investigative ophthalmology & visual science.

[27]  F. Glorieux,et al.  Correction of the abnormal mineral ion homeostasis with a high-calcium, high-phosphorus, high-lactose diet rescues the PDDR phenotype of mice deficient for the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1). , 2003, Bone.

[28]  F. Glorieux,et al.  Conventional and tissue‐specific inactivation of the 25‐hydroxyvitamin D‐1α‐hydroxylase (CYP27B1) , 2003, Journal of cellular biochemistry.

[29]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[30]  R. Balling,et al.  Deletion of deoxyribonucleic acid binding domain of the vitamin D receptor abrogates genomic and nongenomic functions of vitamin D. , 2002, Molecular endocrinology.

[31]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[33]  N. Amizuka,et al.  Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Baron,et al.  Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Tatsuya Yoshizawa,et al.  Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning , 1997, Nature Genetics.

[36]  A. Poustka,et al.  A gene (PEX) with homologies to endopeptidases is mutated in patients with X–linked hypophosphatemic rickets , 1995, Nature Genetics.

[37]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[38]  E. Ogata,et al.  Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production. , 1989, Endocrinology.

[39]  R. Gray,et al.  Evidence that low plasma 1,25‐dihydroxyvitamin D causes intestinal malabsorption of calcium and phosphate in juvenile X‐linked hypophosphatemic mice , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  G. Dickson.  Methods of Calcified Tissue Preparation , 1984 .

[41]  H. Tenenhouse.  Investigation of the mechanism for abnormal renal 25-hydroxyvitamin D3-1-hydroxylase activity in the X-linked Hyp mouse. , 1984, Endocrinology.

[42]  M J McLeod,et al.  Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. , 1980, Teratology.

[43]  F. Glorieux,et al.  Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Glorieux,et al.  Rescue of the phenotype of CYP27B1 (1alpha-hydroxylase)-deficient mice. , 2004, The Journal of steroid biochemistry and molecular biology.

[45]  J. Prud’homme,et al.  Targeted inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. , 2001, Endocrinology.

[46]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[47]  S. Krane,et al.  Printed in U.S.A. Copyright © 1998 by The Endocrine Society The Parathyroid Hormone (PTH)/PTH-Related Peptide Receptor Mediates Actions of Both Ligands in , 2022 .